| A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations (NCT07629960) | Blueprint Medicines Corporation | 2026-06-04 |
| An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) (NCT07264959) | Blueprint Medicines Corporation | 2026-04-15 |
| A Study of Elenestinib in Healthy Adult Female Participants (NCT07388511) | Blueprint Medicines Corporation | 2026-02-05 |
| A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany (NCT07255638) | Blueprint Medicines Corporation | 2025-12-09 |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations (NCT07143669) | Blueprint Medicines Corporation | 2025-10-17 |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) (NCT06931405) | Blueprint Medicines Corporation | 2025-05-28 |
| Study of BLU-808 in Allergic Rhinoconjunctivitis (NCT06922448) | Blueprint Medicines Corporation | 2025-04-14 |
| Avapritinib Rollover Study (NCT06748001) | Blueprint Medicines Corporation | 2024-11-28 |
| Study of BLU-808 in Healthy Adult Participants (NCT06948032) | Blueprint Medicines Corporation | 2024-08-07 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (NCT05609942) | Blueprint Medicines Corporation | 2023-09-25 |
| A Drug-drug Interaction Study of Avapritinib and Midazolam (NCT04908176) | Blueprint Medicines Corporation | 2022-08-24 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873) | Blueprint Medicines Corporation | 2022-03-04 |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling (NCT04773782) | Blueprint Medicines Corporation | 2022-02-24 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis (NCT04910685) | Blueprint Medicines Corporation | 2021-11-30 |
| (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation (NCT04811365) | Blueprint Medicines Corporation | 2021-06-29 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC (NCT04862780) | Blueprint Medicines Corporation | 2021-06-29 |
| Study for Patients Previously Treated in Avapritinib Clinical Trials (NCT04825574) | Blueprint Medicines Corporation | 2021-05-21 |
| Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM (NCT04695431) | Blueprint Medicines Corporation | 2020-12-02 |
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (NCT03580655) | Blueprint Medicines Corporation | 2018-11-21 |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST (NCT03465722) | Blueprint Medicines Corporation | 2018-03-26 |